Trade Cerevel Therapeutics Holdings, Inc. - CERE CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 0.11 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.030779% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | -0.013666% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Key Stats
| Prev. Close* | 26.94 |
| Open* | 25.72 |
| 1-Year Change* | -4.56% |
| Day's Range* | 25.72 - 27.24 |
| 52 wk Range | 19.86-41.46 |
| Average Volume (10 days) | 561.18K |
| Average Volume (3 months) | 12.60M |
| Market Cap | 4.55B |
| P/E Ratio | -100.00K |
| Shares Outstanding | 156.32M |
| Revenue | N/A |
| EPS | -2.13 |
| Dividend (Yield %) | N/A |
| Beta | -100.00K |
| Next Earnings Date | Feb 27, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jun 29, 2022 | 26.95 | 1.81 | 7.20% | 25.14 | 27.30 | 25.14 |
| Jun 28, 2022 | 26.94 | -0.93 | -3.34% | 27.87 | 29.13 | 26.80 |
| Jun 27, 2022 | 28.99 | 0.89 | 3.17% | 28.10 | 29.70 | 27.49 |
| Jun 24, 2022 | 28.08 | -0.17 | -0.60% | 28.25 | 29.09 | 27.63 |
| Jun 23, 2022 | 28.54 | 3.28 | 12.98% | 25.26 | 28.60 | 25.26 |
| Jun 22, 2022 | 26.05 | 1.34 | 5.42% | 24.71 | 26.24 | 24.71 |
| Jun 21, 2022 | 25.15 | -0.32 | -1.26% | 25.47 | 25.47 | 24.03 |
| Jun 17, 2022 | 23.86 | 0.20 | 0.85% | 23.66 | 24.42 | 23.16 |
| Jun 16, 2022 | 22.85 | -1.18 | -4.91% | 24.03 | 24.03 | 22.07 |
| Jun 15, 2022 | 24.53 | 0.31 | 1.28% | 24.22 | 24.87 | 23.33 |
| Jun 14, 2022 | 24.22 | 0.64 | 2.71% | 23.58 | 25.12 | 23.54 |
| Jun 13, 2022 | 23.87 | -0.71 | -2.89% | 24.58 | 24.67 | 23.20 |
| Jun 10, 2022 | 25.82 | -0.27 | -1.03% | 26.09 | 27.04 | 25.60 |
| Jun 9, 2022 | 27.99 | 0.51 | 1.86% | 27.48 | 28.92 | 27.48 |
| Jun 8, 2022 | 28.49 | 1.30 | 4.78% | 27.19 | 29.41 | 27.19 |
| Jun 7, 2022 | 28.72 | 3.24 | 12.72% | 25.48 | 28.84 | 25.48 |
| Jun 6, 2022 | 25.86 | -1.88 | -6.78% | 27.74 | 28.32 | 25.13 |
| Jun 3, 2022 | 27.78 | 1.02 | 3.81% | 26.76 | 28.51 | 26.76 |
| Jun 2, 2022 | 26.98 | 1.06 | 4.09% | 25.92 | 27.80 | 25.30 |
| Jun 1, 2022 | 26.37 | 0.40 | 1.54% | 25.97 | 26.76 | 25.02 |
Cerevel Therapeutics Holdings, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2019 | 2020 | 2021 | |
|---|---|---|---|
| Total revenue | 0 | 0 | 0 |
| Operating Income | 0 | -149.116 | -220.098 |
| Dilution Adjustment | 0 | ||
| Diluted Net Income | 0 | -148.271 | -225.334 |
| Total Operating Expense | 149.116 | 220.098 | |
| Selling/General/Admin. Expenses, Total | 45.813 | 58.243 | |
| Research & Development | 103.303 | 161.855 | |
| Interest Income (Expense), Net Non-Operating | 0.224 | 0.157 | |
| Other, Net | -3.274 | -5.393 | |
| Net Income Before Taxes | -152.166 | -225.334 | |
| Net Income After Taxes | -152.142 | -225.334 | |
| Net Income Before Extra. Items | -152.142 | -225.334 | |
| Net Income | -152.142 | -225.334 | |
| Total Adjustments to Net Income | 3.871 | 0 | |
| Income Available to Common Excl. Extra. Items | -148.271 | -225.334 | |
| Income Available to Common Incl. Extra. Items | -148.271 | -225.334 | |
| Diluted Weighted Average Shares | 73.6433 | 136.577 | |
| Diluted EPS Excluding Extraordinary Items | -2.01337 | -1.64987 | |
| Diluted Normalized EPS | -2.01337 | -1.64987 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 50.571 | 50.51 | 54.527 | 64.49 | 72.53 |
| Selling/General/Admin. Expenses, Total | 14.01 | 13.216 | 14.368 | 16.649 | 17.507 |
| Research & Development | 36.561 | 37.294 | 40.159 | 47.841 | 55.023 |
| Operating Income | -50.571 | -50.51 | -54.527 | -64.49 | -72.53 |
| Interest Income (Expense), Net Non-Operating | 0.015 | 0.01 | 0.013 | 0.119 | 0.295 |
| Other, Net | -0.425 | -2.739 | -7.545 | 5.316 | 3.941 |
| Net Income Before Taxes | -50.981 | -53.239 | -62.059 | -59.055 | -68.294 |
| Net Income After Taxes | -50.981 | -53.239 | -62.059 | -59.055 | -68.294 |
| Net Income Before Extra. Items | -50.981 | -53.239 | -62.059 | -59.055 | -68.294 |
| Net Income | -50.981 | -53.239 | -62.059 | -59.055 | -68.294 |
| Income Available to Common Excl. Extra. Items | -50.981 | -53.239 | -62.059 | -59.055 | -68.294 |
| Income Available to Common Incl. Extra. Items | -50.981 | -53.239 | -62.059 | -59.055 | -68.294 |
| Diluted Net Income | -50.981 | -53.239 | -62.059 | -59.055 | -68.294 |
| Diluted Weighted Average Shares | 127.226 | 127.482 | 144.022 | 147.392 | 147.985 |
| Diluted EPS Excluding Extraordinary Items | -0.40071 | -0.41762 | -0.4309 | -0.40067 | -0.46149 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.40071 | -0.41762 | -0.4309 | -0.40067 | -0.46149 |
- Annual
- Quarterly
| 2019 | 2020 | 2021 | |
|---|---|---|---|
| Total Current Assets | 390.56 | 578.017 | |
| Cash and Short Term Investments | 383.623 | 565.688 | |
| Cash & Equivalents | 383.623 | 193.018 | |
| Prepaid Expenses | 6.777 | 11.6 | |
| Other Current Assets, Total | 0.16 | 0.729 | |
| Total Assets | 445.273 | 688.919 | |
| Property/Plant/Equipment, Total - Net | 48.624 | 51.7 | |
| Property/Plant/Equipment, Total - Gross | 48.706 | 54.266 | |
| Accumulated Depreciation, Total | -0.082 | -2.566 | |
| Other Long Term Assets, Total | 6.089 | 6.933 | |
| Total Current Liabilities | 29.548 | 42.538 | |
| Accounts Payable | 4.993 | 11.298 | |
| Accrued Expenses | 24.282 | 30.865 | |
| Notes Payable/Short Term Debt | 0 | 0 | |
| Other Current Liabilities, Total | 0.273 | 0.375 | |
| Total Liabilities | 60.753 | 110.19 | |
| Total Long Term Debt | 0 | 33.54 | |
| Other Liabilities, Total | 31.205 | 34.112 | |
| Total Equity | 384.52 | 578.729 | |
| Common Stock | 0.013 | 0.015 | |
| Additional Paid-In Capital | 775.417 | 1195.94 | |
| Retained Earnings (Accumulated Deficit) | -390.91 | -616.244 | |
| Total Liabilities & Shareholders’ Equity | 445.273 | 688.919 | |
| Total Common Shares Outstanding | 127.124 | 147.72 | |
| Short Term Investments | 372.67 | ||
| Long Term Investments | 52.269 | ||
| Long Term Debt | 33.54 | ||
| Other Equity, Total | -0.986 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 349.811 | 331.782 | 675.029 | 578.017 | 553.55 |
| Cash and Short Term Investments | 343.287 | 327.06 | 669.676 | 565.688 | 542.944 |
| Cash & Equivalents | 343.287 | 327.06 | 669.676 | 193.018 | 91.764 |
| Prepaid Expenses | 6.362 | 4.597 | 5.257 | 11.6 | 10.004 |
| Other Current Assets, Total | 0.162 | 0.125 | 0.096 | 0.729 | 0.602 |
| Total Assets | 408.104 | 391.004 | 733.48 | 688.919 | 618.552 |
| Property/Plant/Equipment, Total - Net | 51.784 | 51.92 | 51.98 | 51.7 | 52.663 |
| Property/Plant/Equipment, Total - Gross | 51.876 | 52.552 | 53.526 | 54.266 | 56.299 |
| Accumulated Depreciation, Total | -0.092 | -0.632 | -1.546 | -2.566 | -3.636 |
| Other Long Term Assets, Total | 6.509 | 7.302 | 6.471 | 6.933 | 4.411 |
| Total Current Liabilities | 34.151 | 29.257 | 30.8 | 42.538 | 35.318 |
| Accounts Payable | 7.755 | 4.986 | 5.445 | 11.298 | 8.183 |
| Accrued Expenses | 26.241 | 23.939 | 24.928 | 30.865 | 26.442 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.155 | 0.332 | 0.427 | 0.375 | 0.693 |
| Total Liabilities | 68.068 | 97.117 | 104.4 | 110.19 | 97.053 |
| Total Long Term Debt | 0 | 32.242 | 38.612 | 33.54 | 28.324 |
| Other Liabilities, Total | 33.917 | 35.618 | 34.988 | 34.112 | 33.411 |
| Total Equity | 340.036 | 293.887 | 629.08 | 578.729 | 521.499 |
| Common Stock | 0.013 | 0.013 | 0.015 | 0.015 | 0.015 |
| Additional Paid-In Capital | 781.914 | 789.004 | 1186.79 | 1195.94 | 1207.36 |
| Retained Earnings (Accumulated Deficit) | -441.891 | -495.13 | -557.189 | -616.244 | -684.538 |
| Total Liabilities & Shareholders’ Equity | 408.104 | 391.004 | 733.48 | 688.919 | 618.552 |
| Total Common Shares Outstanding | 127.325 | 127.585 | 147.136 | 147.72 | 148.183 |
| Long Term Debt | 32.242 | 38.612 | 33.54 | 28.324 | |
| Other Equity, Total | -0.533 | -0.986 | -1.334 | ||
| Short Term Investments | 372.67 | 451.18 | |||
| Long Term Investments | 52.269 | 7.928 |
- Annual
- Quarterly
| 2019 | 2020 | 2021 | |
|---|---|---|---|
| Net income/Starting Line | -152.142 | -225.334 | |
| Cash From Operating Activities | -117.802 | -178.546 | |
| Cash From Operating Activities | 0.397 | 2.731 | |
| Non-Cash Items | 16.236 | 28.516 | |
| Changes in Working Capital | 17.707 | 15.541 | |
| Cash From Investing Activities | -18.892 | -435.661 | |
| Capital Expenditures | -18.892 | -10.503 | |
| Cash From Financing Activities | 440.835 | 423.602 | |
| Financing Cash Flow Items | 440.835 | -0.355 | |
| Net Change in Cash | 304.141 | -190.605 | |
| Other Investing Cash Flow Items, Total | -425.158 | ||
| Issuance (Retirement) of Stock, Net | 392.707 | ||
| Issuance (Retirement) of Debt, Net | 31.25 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -50.981 | -104.22 | -166.279 | -225.334 | -68.294 |
| Cash From Operating Activities | -36.418 | -82.026 | -125.802 | -178.546 | -67.648 |
| Cash From Operating Activities | 0.063 | 0.664 | 1.644 | 2.731 | 1.118 |
| Non-Cash Items | 6.377 | 14.084 | 27.551 | 28.516 | 4.935 |
| Changes in Working Capital | 8.123 | 7.446 | 11.282 | 15.541 | -5.407 |
| Cash From Investing Activities | -4.66 | -8.243 | -9.431 | -435.661 | -38.542 |
| Capital Expenditures | -4.66 | -8.243 | -9.431 | -10.503 | -2.197 |
| Cash From Financing Activities | 0.742 | 33.706 | 421.286 | 423.602 | 2.603 |
| Issuance (Retirement) of Stock, Net | 0.742 | 2.571 | 390.036 | 392.707 | 2.854 |
| Net Change in Cash | -40.336 | -56.563 | 286.053 | -190.605 | -103.587 |
| Financing Cash Flow Items | -0.115 | 0 | -0.355 | -0.251 | |
| Issuance (Retirement) of Debt, Net | 31.25 | 31.25 | 31.25 | ||
| Other Investing Cash Flow Items, Total | -425.158 | -36.345 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Bain Capital Private Equity, LP | Private Equity | 38.7867 | 60632356 | 0 | 2022-09-30 | LOW |
| Pfizer Inc | Corporation | 17.4954 | 27349211 | 0 | 2022-08-16 | MED |
| Fidelity Management & Research Company LLC | Investment Advisor | 14.5762 | 22785810 | 1072862 | 2022-09-30 | LOW |
| Perceptive Advisors LLC | Private Equity | 4.1656 | 6511727 | 0 | 2022-09-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.7506 | 5863050 | 861581 | 2022-09-30 | LOW |
| T. Rowe Price Associates, Inc. | Investment Advisor | 3.0327 | 4740842 | -1555066 | 2022-09-30 | LOW |
| Federated Hermes Global Investment Management Corp. | Investment Advisor/Hedge Fund | 2.1195 | 3313333 | 200000 | 2022-09-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.025 | 3165508 | 43098 | 2022-09-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.7395 | 2719272 | 304798 | 2022-09-30 | LOW |
| Rock Springs Capital Management LP | Hedge Fund | 1.5987 | 2499148 | 732007 | 2022-09-30 | LOW |
| T. Rowe Price Investment Management, Inc. | Investment Advisor | 1.2803 | 2001437 | 2001437 | 2022-09-30 | HIGH |
| Invus Public Equities Advisors, LLC | Investment Advisor | 1.2794 | 2000000 | 500000 | 2022-09-30 | LOW |
| Janus Henderson Investors | Investment Advisor/Hedge Fund | 0.8847 | 1382960 | 1369554 | 2022-09-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7256 | 1134261 | 81971 | 2022-09-30 | LOW |
| Lord, Abbett & Co. LLC | Investment Advisor | 0.6947 | 1085956 | 82992 | 2022-09-30 | MED |
| Point72 Asset Management, L.P. | Hedge Fund | 0.6936 | 1084240 | 881940 | 2022-09-30 | HIGH |
| Alkeon Capital Management LLC | Investment Advisor/Hedge Fund | 0.6291 | 983408 | -35667 | 2022-09-30 | LOW |
| Hood River Capital Management LLC | Investment Advisor | 0.5735 | 896572 | 473322 | 2022-09-30 | MED |
| BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.4714 | 736972 | 11220 | 2022-09-30 | LOW |
| Novalis LifeSciences LLC | Private Equity | 0.4052 | 633350 | 0 | 2022-03-31 |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group +485000+
Traders
65000+
Active clients monthly
$48000000+
Monthly investing volume
$28000000+
Try now Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Leverage
20:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Cerevel Therapeutics Holdings, Inc. Company profile
About Cerevel Therapeutics Holdings Inc
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company combines an understanding of disease-related biology and neurocircuitry of the brain with chemistry and central nervous system (CNS), receptor pharmacology to discover and design new therapies. The Company is engaged in the development of new therapies for neuroscience diseases, including schizophrenia, epilepsy and Parkinson’s disease. The Company’s product candidate includes CVL-231, Darigabat, Tavapadon, CVL-871 and CVL-936. The Company’s product candidate CVL-231 for the treatment of schizophrenia. Its Darigabat for the treatment of both epilepsy and anxiety. Its Tavapadon is a dopamine D1/D5 partial agonist for the treatment of early- and late-stage Parkinson’s disease. Its product candidate CVL-871 for the treatment of dementia-related apathy. Its CVL-936 for the treatment of substance use disorder (SUD).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cerevel Therapeutics Holdings Inc revenues was not reported. Net loss applicable to common stockholders increased 52% to $225.3M. Higher net loss reflects Research and development increase of 57% to $161.9M (expense), General and administrative increase of 27% to $58.2M (expense), Other income (expense), net increase of 65% to $5.4M (expense).
| Industry: | Bio Therapeutic Drugs |
222 Jacobs Street
Suite 200
CAMBRIDGE
MASSACHUSETTS 02141
US
Income Statement
News
S&P 500, Nasdaq, DAX 40, Hang Seng technical update
Can the S&P 500 hold above its 2022 descending trend line?
12:44, 26 January 2023
Amazon Q4 earnings: online retailer to feel the pinch of higher costs and slowing consumer spending
AMZN Q4 earnings preview and technical analysis
09:59, 25 January 2023
Canadian Dollar Forecast: Bank of Canada Heading Towards a Final Rate Hike
Bank of Canada expected to hike 25bps at its upcoming meeting. Focus on whether the BoC announces a pause going forward.
15:49, 24 January 2023
Alphabet Q4 earnings: has google’s advertising revenue held up despite recession fears?
A preview of Google parent company Alphabet's fourth-quarter earnings after announcing its plans to cut 12,000 jobs.
11:47, 24 January 2023
FX Weekly Outlook: USD/JPY, EUR/USD Analysis
USD, USD/JPY, EUR/USD forecasts for the week ahead.
14:06, 20 January 2023People also watch
Still looking for a broker you can trust?
Join the 480.000+ traders worldwide that chose to trade with Capital.com